Xiaodong Wang Biography and Net Worth

Insider of BeiGene

Xiaodong Wang, Ph.D., is our Co-Founder and has served as the Chairman of our Scientific Advisory Board since 2011. Dr. Wang became a member of our Board of Directors in February 2016. Dr. Wang has served as the founding Director of the National Institute of Biological Sciences in Beijing since 2003 and became its Director and Investigator in 2010. Previously, he was a Howard Hughes Medical Institute Investigator from 1997 to 2010 and held the position of the George L. MacGregor Distinguished Chair Professor in Biomedical Sciences at the University of Texas Southwestern Medical Center in Dallas, Texas from 2001 to 2010. In 2004, Dr. Wang founded Joyant Pharmaceuticals, Inc., a venture capital-backed biotechnology company focused on the development of small molecule therapeutics for cancer. Dr. Wang received his Ph.D. in Biochemistry from the University of Texas Southwestern Medical Center and B.S. in Biology from Beijing Normal University. Dr. Wang has been a member of the National Academy of Science, USA, since 2004 and a foreign associate of the Chinese Academy of Sciences since 2013.

What is Xiaodong Wang's net worth?: The estimated net worth of Xiaodong Wang is at least $0.00 as of March 4th, 2025. Dr. Wang owns 5,240,882 shares of BeiGene stock worth more than $0 as of March 31st. This net worth evaluation does not reflect any other assets that Dr. Wang may own. Additionally, Dr. Wang receives an annual salary of $250,000.00 as Insider at BeiGene. Learn More about Xiaodong Wang's net worth.
How old is Xiaodong Wang?: Dr. Wang is currently 61 years old. There are 2 older executives and no younger executives at BeiGene. The oldest executive at BeiGene is Dr. Xiaobin Wu Ph.D., President & COO, who is 62 years old. Learn More on Xiaodong Wang's age.
What is Xiaodong Wang's salary?: As the Insider of BeiGene, Ltd., Dr. Wang earns $250,000.00 per year. There are 3 executives that earn more than Dr. Wang. The highest earning executive at BeiGene is Mr. John V. Oyler, Founder, Executive Chairman & CEO, who commands a salary of $2,050,000.00 per year. Learn More on Xiaodong Wang's salary.
How do I contact Xiaodong Wang?: The corporate mailing address for Dr. Wang and other BeiGene executives is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. BeiGene can also be reached via phone at (345) 949-4123 and via email at ir@beigene.com. Learn More on Xiaodong Wang's contact information.
Has Xiaodong Wang been buying or selling shares of BeiGene?: Xiaodong Wang has not been actively trading shares of BeiGene during the last quarter. Most recently, Xiaodong Wang sold 41,760 shares of the business's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $186.90, for a transaction totalling $7,804,944.00. Learn More on Xiaodong Wang's trading history.
Who are BeiGene's active insiders?: BeiGene's insider roster includes Timothy Chen (Director), Donald Glazer (Director), Jane Huang (CMO), Chan Lee (SVP), Howard Liang (CFO), John Oyler (Founder, Executive Chairman & CEO), Corazon (Corsee) Sanders (Director), Julia Wang (CFO), Lai Wang (Insider), Xiaodong Wang (Insider), and Xiaobin Wu (COO). Learn More on BeiGene's active insiders.
Are insiders buying or selling shares of BeiGene?: During the last twelve months, insiders at the sold shares 17 times. They sold a total of 1,176,548 shares worth more than $219,768,883.46. The most recent insider tranaction occured on December, 10th when insider Xiaodong Wang sold 41,760 shares worth more than $7,804,944.00. Insiders at BeiGene own 7.4% of the company. Learn More about insider trades at BeiGene.
Information on this page was last updated on 12/10/2024.

Xiaodong Wang Insider Trading History at BeiGene

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/10/2024	Sell	41,760	$186.90	$7,804,944.00
11/26/2024	Sell	40,468	$190.10	$7,692,966.80
3/8/2023	Sell	67,635	$226.03	$15,287,539.05
1/11/2023	Sell	2,500	$252.66	$631,650.00	5,512,556
1/9/2023	Sell	900	$250.00	$225,000.00
12/13/2022	Sell	3,013	$211.33	$636,737.29	5,577,556
11/15/2022	Sell	1,987	$210.14	$417,548.18	5,629,556
5/10/2021	Sell	3,394	$300.46	$1,019,761.24	5,747,271
10/16/2020	Sell	5,000	$320.00	$1,600,000.00	7,201,009
10/5/2020	Sell	5,000	$300.00	$1,500,000.00	7,201,009
9/25/2020	Sell	5,000	$280.42	$1,402,100.00	7,201,009
9/17/2020	Sell	5,000	$260.27	$1,301,350.00	7,201,009
8/10/2020	Sell	4,000	$211.06	$844,240.00	7,201,009
7/7/2020	Sell	6,000	$200.00	$1,200,000.00	7,267,569
6/22/2020	Sell	5,000	$181.33	$906,650.00	7,330,580
3/4/2020	Sell	5,000	$157.14	$785,700.00	7,395,580
11/14/2019	Sell	8,504	$193.31	$1,643,908.24	7,460,580
11/4/2019	Sell	1,000	$190.00	$190,000.00	7,585,628
11/1/2019	Sell	1,000	$170.00	$170,000.00	7,585,628
7/1/2019	Sell	4,847	$126.46	$612,951.62	7,611,628
3/1/2019	Sell	5,000	$146.82	$734,100.00
12/3/2018	Sell	5,000	$152.41	$762,050.00	2,329
11/19/2018	Sell	5,000	$124.30	$621,500.00	3,900
8/13/2018	Sell	3,449	$158.77	$547,597.73
7/12/2017	Sell	20,000	$72.44	$1,448,800.00	16,300
6/28/2017	Sell	35,000	$44.95	$1,573,250.00	26,600
6/2/2017	Sell	5,539	$40.00	$221,560.00	55,000
5/4/2017	Sell	14,461	$40.80	$590,008.80	65,030
4/5/2017	Sell	11,650	$36.83	$429,069.50	81,194
3/24/2017	Sell	38,107	$36.96	$1,408,434.72	116,478
3/10/2017	Sell	36,892	$39.89	$1,471,621.88	150,657
2/27/2017	Sell	38,351	$38.19	$1,464,624.69	194,495

See Full Table

Xiaodong Wang Buying and Selling Activity at BeiGene

BeiGene Company Overview

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Today's Range

Now: N/A

50 Day Range

MA: $194.32

$174.72

$217.22

2 Week Range

Now: N/A

Volume

331,608 shs

Average Volume

282,883 shs

Market Capitalization

$18.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

Xiaodong Wang Biography and Net Worth

What is Xiaodong Wang's net worth?

How old is Xiaodong Wang?

What is Xiaodong Wang's salary?

How do I contact Xiaodong Wang?

Has Xiaodong Wang been buying or selling shares of BeiGene?

Who are BeiGene's active insiders?

Are insiders buying or selling shares of BeiGene?